BMA Of South Greensboro Inc is a medicare approved dialysis facility center in Greensboro, North Carolina and it has 49 dialysis stations. It is located in Guilford county at 622 Industrial Avenue, Greensboro, NC, 27406. You can reach out to the office of BMA Of South Greensboro Inc at (336) 271-8178. This dialysis clinic is managed and/or owned by Fresenius Medical Care. BMA Of South Greensboro Inc has the following ownership type - Profit. It was first certified by medicare in August, 1989. The medicare id for this facility is 342537 and it accepts patients under medicare ESRD program.
| Name | BMA Of South Greensboro Inc |
|---|---|
| Location | 622 Industrial Avenue, Greensboro, North Carolina |
| No. of Dialysis Stations | 49 |
| Medicare ID | 342537 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 622 Industrial Avenue, Greensboro, North Carolina, 27406 | |
| (336) 271-8178 | |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
| NPI Number | 1134231962 |
| Organization Name | Bma South Greensboro |
| Doing Business As | Bio-medical Applications Of North Carolina, Inc. |
| Address | 622 Industrial Ave Greensboro, North Carolina, 27406 |
| Phone Number | (336) 271-8178 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 66% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 22% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 14% |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 54% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 25% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 52% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 78% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 22% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 93 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 5 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 195 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1819 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at BMA Of South Greensboro Inc with elevated calcium levels.
| Patients with hypercalcemia | 208 |
| Hypercalcemia patient months | 1933 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 216 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 25 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 27 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 144 |
| Patient months included in arterial venous fistula and catheter summaries | 1221 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 61 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 170 |
| Hospitalization Rate in facility | 189 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 278.6 |
| Hospitalization Rate: Lower Confidence Limit | 136 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at BMA Of South Greensboro Inc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 18.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 23.9 |
| Readmission Rate: Lower Confidence Limit | 14.2 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at BMA Of South Greensboro Inc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.98 (Worse than Expected) |
| SIR: Upper Confidence Limit | 2.95 |
| SIR: Lower Confidence Limit | 1.27 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether BMA Of South Greensboro Inc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 154 |
| Transfusion Rate in facility | 25.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 52.9 |
| Transfusion Rate: Lower Confidence Limit | 13.3 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at BMA Of South Greensboro Inc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 859 |
| Mortality Rate in facility | 16.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20.1 |
| Mortality Rate: Lower Confidence Limit | 13.5 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago
Greensboro Kidney Center Location: 2700 Henry Street, Greensboro, North Carolina, 27405 Phone: (336) 375-1400 |
BMA Of South Greensboro Inc Location: 622 Industrial Avenue, Greensboro, North Carolina, 27406 Phone: (336) 271-8178 |
BMA Northwest Greensboro Kidney Center Location: 2837 Horsepen Creek, Greensboro, North Carolina, 27410 Phone: (336) 664-6869 |
FMC Of East Greensboro Location: 3839 Burlington Road, Greensboro, North Carolina, 27405 Phone: (336) 358-1233 |
News Archive
Creating the industry's first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.
The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.
In recognition of World Polio Day, Rotary clubs are celebrating a major milestone reached in the humanitarian service organization's global fundraising campaign to- with nearly US$100 million ($99 million to date) raised.
› Verified 6 days ago